证券代码：688117 证券简称：圣诺生物 公告编号：2026-003 成都圣诺生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以成都圣诺生物 科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币元 ■ 3、影响经营业绩的主要因素 报告期内，公司持续专注于主营业务多肽药物CDMO、原料药和制剂的协同发展，得益于全球多肽药物 市场降糖、减重领域的药品需求持续放量，使得公司GLP-1原料药销量大增，经营业绩大幅提升。 （二）上表中有关项目增减变动幅度达30%以上的主要原因 注：1.本报告期初数同法定披露的上年年末数。 2.表中财务数据及指标均以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准；表 中增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状 ...

报告期内，公司持续专注于主营业务多肽药物CDMO、原料药和制剂的协同发展，得益于全球多肽药物 市场降糖、减重领域的药品需求持续放量，使得公司GLP-1原料药销量大增，经营业绩大幅提升。 格隆汇2月27日丨圣诺生物(688117.SH)公布2025年度业绩快报，2025年度公司实现营业收入7.41亿元， 较上年同期增长62.55%；实现归属于母公司所有者的净利润1.66亿元，较上年同期增长231.49%；实现 归属于母公司所有者的扣除非经常性损益的净利润1.73亿元，较上年同期增长278.52%。 ...

证券日报网讯 2月27日，圣诺生物发布公告称，公司2025年度实现营业总收入741，343，445.99元，同 比增长62.55%；归属于母公司所有者的净利润为165，823，888.08元，同比增长231.49%。 （文章来源：证券日报） ...

成都圣诺生物科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688117 证券简称：圣诺生物 公告编号：2026-003 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以成都圣诺生物科技股份有限公司（以下简称"公司"）2025 年 年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | | --- | --- | --- | --- | --- | | | | | （％） | | | 营业总收入 | 741,343,445.99 | 456,070,000.10 | | 62.55 | | 营业利润 | 200,844,661.43 | 62,060,538.67 | | 223.63 | | 利润总额 | 188,030,381.81 | 61,508,550.12 | | 205.70 | | 归属于母公司所有 者的净利润 ...

圣诺生物发布业绩快报，2025年度公司实现营业收入7.41亿元，较上年同期增长62.55%；实现归属于母 公司所有者的净利润1.66亿元，较上年同期增长231.49%；实现归属于母公司所有者的扣除非经常性损 益的净利润1.73亿元，较上年同期增长278.52%。 ...

Recent Events - The company announced on February 11, 2026, that its wholly-owned subsidiary, Chengdu Saintno Biological Pharmaceutical Co., Ltd., is participating in the national organized procurement of medicines, with multiple products (such as Acetate Octreotide Injection and Thymosin Alpha 1 Injection) expected to be selected. The results of the selection are anticipated to be officially implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028. This event may impact future sales scale and market share [2]. Performance and Operations - The company released a profit forecast on January 16, 2026, indicating a significant year-on-year increase in net profit attributable to the owners of the parent company. However, specific financial data will be confirmed in the subsequent audited annual report, the release date of which has not yet been announced. Attention should be paid to official communications from the company [3].

Industry Overview - Peptides are bioactive fragments of proteins that can be rapidly absorbed and utilized by the human body, providing energy and nutrients to cells. Their potential has been further released since the Human Genome Project in the 1990s, leading to unprecedented prosperity in peptide research and applications, especially in the pharmaceutical field [1][13] - The Chinese peptide industry market size is projected to grow from 57.34 billion yuan in 2016 to 209.12 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.56%. By 2025, the market size is expected to reach approximately 247.6 billion yuan [1][13] Market Segmentation - The peptide industry value chain consists of upstream raw materials and equipment (amino acids, amino acid protectants, resin acids, synthesis instruments, packaging materials), midstream production and manufacturing, and downstream applications in food, pharmaceuticals, feed, health products, and cosmetics [9][11] - The global peptide drug market is expected to reach approximately 96 billion USD by 2025, driven by the increasing prevalence of chronic diseases and the unique advantages of peptide drugs in treatment [12][17] Key Companies - HanYue Pharmaceutical focuses on four main areas: peptide formulations, raw materials, small nucleic acids, and CRDMO services. The company has achieved significant revenue growth, with a reported 114.86% increase in pharmaceutical manufacturing revenue in the first half of 2025 [20][21] - ZhongPeptide Biochemical Co., Ltd. specializes in contract research, development, and production of peptides and small nucleic acids, providing comprehensive services from early discovery to commercial production [21] Development Trends - The Chinese peptide industry is transitioning from traditional chemical synthesis to a deep integration of biotechnology and synthetic biology, enhancing production efficiency and reducing costs [22][24] - The application of peptides is rapidly expanding beyond pharmaceuticals into health, beauty, and functional food markets, with increasing consumer demand for personalized health solutions [23][24] - The industry is also moving towards green manufacturing and sustainable development, focusing on reducing environmental footprints and enhancing social responsibility [24]

Core Viewpoint - Chengdu Shengnuo Biotechnology Co., Ltd. announced its participation in the national organized procurement of pharmaceuticals, with several products expected to be selected for the new round of procurement, which is a significant step for the company in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1][2]. Group 1: Selected Products - The company’s subsidiary, Chengdu Shengnuo Pharmaceutical Co., Ltd., participated in the national organized procurement for the first to eighth batches, with products such as Acetate Octreotide Injection and Acetate Atosiban Injection expected to be selected [1]. - The selected products include Acetate Octreotide Injection (seventh batch), Acetate Atosiban Injection (eighth batch), Somatostatin Injection (eighth batch), Thymosin Alpha 1 Injection, and Eptifibatide Injection [1]. Group 2: Impact on the Company - The selected products are expected to enhance the company's sales revenue significantly in 2024 and the first nine months of 2025, with the procurement cycle running until the end of 2028 [2]. - The procurement will prioritize the use of selected drugs in medical institutions, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's operational development [2]. - The selection also reflects the stability and reliability of the company's drug quality, which is crucial for its competitive position in the peptide pharmaceutical market [2].

圣诺生物(688117.SH)发布公告，公司全资子公司成都圣诺生物制药有限公司于近日参与了国家组织的 第一批至第八批国家集采药品新一轮接续采购工作，本次接续采购是国家组织集采的化学药品首次开展 全国范围统一接续，根据《国家组织集采药品协议期满品种接续采购拟中选结果表》(LC-YPJX-2026-1) 显示，公司产品醋酸奥曲肽注射剂(第七批中选)、醋酸阿托西班注射剂(第八批中选)、生长抑素注射剂 (第八批中选)与公司新中选产品胸腺法新注射剂、依替巴肽注射剂共同拟中选本次新一轮接续采购。 ...

智通财经APP讯， 圣诺生物(688117.SH)发布公告，公司全资子公司成都圣诺生物制药有限公司于近日 参与了国家组织的第一批至第八批国家集采药品新一轮接续采购工作，本次接续采购是国家组织集采的 化学药品首次开展全国范围统一接续，根据《国家组织集采药品协议期满品种接续采购拟中选结果表》 (LC-YPJX-2026-1)显示，公司产品醋酸奥曲肽注射剂(第七批中选)、醋酸阿托西班注射剂(第八批中 选)、生长抑素注射剂(第八批中选)与公司新中选产品胸腺法新注射剂、依替巴肽注射剂共同拟中选本次 新一轮接续采购。 ...